*Clinical Trial Reported by 'Medicube AGE-R Gluatathione Glow Toner human application test report'
In the ELIXA CVOT, lixisenatide was found to be non-inferior to standard of care plus placebo in terms of risk of the composite endpoint (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina)13.4% in the lixisenatide group and 13.2% in the placebo group (hazard ratio, 1.02
Use this tool as a rough guide to what you can expect, rather than a fixed schedule, since the experience varies from person to person
This drug may cause side effects, including nausea/vomiting, diarrhea, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, gas, hair loss, GERD, abdominal distenision, dizziness and low blood pressure